- Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202
- Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences:
